WuXi AppTec Co., Ltd. Class H (HK:2359) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
WuXi AppTec Co., Ltd. has announced a strategic move to sell its WuXi Advanced Therapies Inc. and Oxford Genetics Limited to Altaris LLC, a U.S.-based healthcare investment fund. This transaction is designed to maintain the delivery of crucial cell therapy services while aligning with WuXi’s commitment to client and patient priorities. Despite the sale, the company’s financial performance remains unaffected, and it continues to pursue its overarching mission to innovate in drug manufacturing and treatment solutions.
For further insights into HK:2359 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Called Out by Trump FCC
- Ford (NYSE:F) Electric Vehicles May Have Tougher Chassis Soon
- Can Intel (NASDAQ:INTC) Come Back in 2025?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
